Articles From: Cardiome Appoints Jürgen Polifka, Ph.D., as General Manager, Sales and Marketing Europe to Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum

Cardiome Appoints Jürgen Polifka, Ph.D., as General Manager, Sales and Marketing Europe Canada NewsWire NASDAQ: CRME   TSX: COM VANCOUVER , April 2, 2013 /CNW/ - Cardiome Pharma Corp.

Cardiome Reports Fourth Quarter and Full Year 2012 Financial Results Canada NewsWire Cardiome to conduct conference call and webcast today, March 15 , at 8:15 a.m. Eastern ( 5:15 a.m. Pacific) NASDAQ: CRME   TSX: COM VANCOUVER , March 15, 2013 /CNW/ - Cardiome Pharma Corp.

Cardiome to conduct conference call and webcast today, March 15 , at 8:15 a.m. Eastern ( 5:15 a.m. Pacific) NASDAQ: CRME   TSX: COM VANCOUVER , March 15, 2013 /PRNewswire/ - Cardiome Pharma Corp.

Cardiome Selects Quintiles To Manage Global Regulatory Affairs And Life Cycle Safety Activities For BRINAVESS™ (Vernakalant Intravenous) Canada NewsWire NASDAQ: CRME   TSX: COM VANCOUVER , Feb.

NASDAQ: CRME   TSX: COM VANCOUVER , Feb.

Cardiome to Hold First Quarter 2013 Financial Results Conference Call on May 13 Canada NewsWire NASDAQ: CRME   TSX: COM VANCOUVER , May 9, 2013 /CNW/ - Cardiome Pharma Corp.

Cardiome to Hold Fourth Quarter and Full Year 2012 Financial Results Conference Call on March 15 Canada NewsWire NASDAQ: CRME   TSX: COM VANCOUVER , March 12, 2013 /CNW/ - Cardiome Pharma Corp.

NASDAQ: CRME   TSX: COM VANCOUVER , March 12, 2013 /PRNewswire/ - Cardiome Pharma Corp.

As health systems are under increasing pressure to share data across systems to improve and expand their networks of care, CardioNet, Inc. and AirStrip have entered into a partnership agreement to develop and co-market an integrated solution for mobile patient monitoring.

CardioNet, Inc. (NASDAQ:BEAT) , the leading wireless medical technology and research services company focused on the diagnosis and monitoring of cardiac arrhythmias, today reported results for the first quarter ended March 31, 2013.

CardioNet, Inc. (NASDAQ:BEAT) , the leading wireless medical technology and research services company with a current focus on the diagnosis and monitoring of cardiac arrhythmias, today reported results for the fourth quarter and full year ended December 31, 2012.

CardioNet, Inc. (NASDAQ:BEAT) will release its first quarter 2013 earnings on Monday, April 22, 2013 at 4:30 PM Eastern Time.

CardioNet, Inc. (“CardioNet” or the “Company”) (NASDAQ:BEAT) , the leading wireless medical technology company focused on diagnosing and monitoring cardiac arrhythmias, announced today that its Board of Directors has approved a plan to adopt a holding company structure to more effectively facilitate its ongoing growth plan.

CardioNet, Inc. (NASDAQ:BEAT) will release its first quarter 2013 earnings on Tuesday, April 23, 2013 at 4:00 PM Eastern Time.

CardioNet, Inc. (NASDAQ:BEAT) will release its fourth quarter and full year 2012 earnings on Wednesday, February 13, 2013 at 4:00 PM Eastern Time.

CardioNet, Inc. (NASDAQ:BEAT) , the leading wireless medical technology and research services company with a current focus on the diagnosis and monitoring of cardiac arrhythmias, today announced a multi-year development agreement with the Belgium-based nanoelectronics research center IMEC and its Dutch affiliate Holst Centre.

Cardiovascular Systems, Inc. (“CSI”) (Nasdaq: CSII) , a medical device company focused on developing and commercializing innovative interventional treatment systems for vascular disease, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) , announced today that it has submitted its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its orbital atherectomy system, used to treat calcified coronary arteries.

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) , presented pivotal 30-day data from its ORBIT II study of severely calcified coronary lesions at the 2013 American College of Cardiology (ACC) conference in San Francisco.

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) , a medical device company focused on developing and commercializing innovative interventional treatment systems for vascular disease, today announced the pricing of an underwritten public offering of 2,000,000 shares of its common stock, at a price to the public of $17.60 per share.

Cardiovascular Systems, Inc. (Nasdaq: CSII) : Revenues of $25.3 million rose 28 percent over the fiscal 2012 second quarter, and 9 percent sequentially over the fiscal 2013 first quarter Stealth 360° ® revenues increased to 93 percent of total device revenues Office-based lab revenues continued to grow at a double-digit consecutive quarter rate ORBIT II coronary trial enrollment has been completed PMA submission of module 3, which includes ORBIT II clinical data, is expected to occur around March 31, 2013 Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal second quarter ended December 31, 2012.

Cardiovascular Systems, Inc. (Nasdaq: CSII) : Revenues of $26.5 million rose 25 percent over the fiscal 2012 third quarter, and 5 percent sequentially over the fiscal 2013 second quarter Stealth 360° ® revenues increased to more than 96 percent of total device revenues Pivotal 30-day data from ORBIT II coronary study presented at ACC Results exceeded trial’s two primary safety and efficacy endpoints by a significant margin PMA submission to treat coronary artery disease completed on March 15 Net proceeds of approximately $38 million raised in public offering of common stock Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) , will present data from its ORBIT II study of coronary artery disease at the 2013 American College of Cardiology (ACC) conference in San Francisco, Mar.

Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII) , will present three-year data from its ORBIT I study of coronary artery disease (CAD) in a poster session at the 2013 Cardiovascular Research Technologies (CRT) conference in Washington, D.C., Feb.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a live webcast of its fiscal 2013 third-quarter conference call on Wednesday, May 1, 2013, at 3:45 p.m. CT (4:45 p.m. ET). David Martin, president and chief executive officer, and Larry Betterley, chief financial officer, will discuss the company’s results for its fiscal third quarter ended March 31, 2013, and its financial outlook.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) , was featured as part of the “Innovation and Technology Adoption” presentation during the Innovations Educational Forum at the 2013 American College of Cardiology (ACC) conference in San Francisco.

SAN DIEGO , April 5, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced that it has entered into a definitive agreement with a single institutional healthcare fund managed by Sabby Management LLC ("Sabby"), the Company's largest shareholder, for a financing of up to $4.0 million in gross proceeds.

SAN DIEGO , April 30, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced that the Company will present a poster demonstrating the clinical benefits of Excellagen ® in advanced regenerative wound management at The Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) meeting to be held May 1-5, 2013 , in Denver, Colorado .

SAN DIEGO , May 2, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced a publication, "Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors", authored by Gabor M Rubanyi, M.D., Ph.D., Cardium's Chief Scientific Officer in the April issue of Molecular Therapy .

New Insights and Discoveries Support Clinical Advancement of Company's Generx® Angiogenic Therapy for Coronary Artery Disease SAN DIEGO , Jan.